Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Discovery Laboratories, Inc. (NASDAQ:DSCO) has been upgraded by TheStreet Ratings from sell to hold. Discovery Laboratories, Inc. (NASDAQ:DSCO) stock performance was -6.01% in last session and finished the day at $2.19. Traded volume was 1,245,476 million shares in the last session and the average volume of the stock remained 589.46 million shares. The beta of the stock remained 1.35. Discovery Laboratories, Inc. (NASDAQ:DSCO) insider ownership is 0.10%.

Shares of CEL-SCI Corporation (NYSEMKT:CVM), have risen nearly 150% since last December, thus placing them firmly alongside other Pharmaceuticals & Biotechnology stocks like Intercept Pharmaceuticals Inc ICPT -0.53% , Rosetta Genomics Ltd. (NASDAQ GS) and IGI Laboratories, Inc. (nysemkt:IG) on the list of early 2014’s Top Healthcare Percentage Gainers. CEL-SCI Corporation (NYSEMKT:CVM) rose/dropped -8.50 percent to $ 1.40 yesterday on volume of 3.64 million shares. The intra-day range of the stock was $ 1.40 to $ 1.62. CEL-SCI Corporation (NYSEMKT:CVM) has a market capitalization of $ 78.32 million.

Cantor Fitzgerald upped their price target on shares of NewLink Genetics Corp. (NASDAQ:NLNK) from $30.00 to $34.00 in a research note issued on Wednesday, American Banking News reports. NewLink Genetics Corp (NASDAQ:NLNK)’s stock on Mar17, 2014 reported a decrease of -9.28% to the closing price of $27.96. Its fifty two weeks range is $11.19 -$53.48. The total market capitalization recorded $779.01 million. The overall volume in the last trading session was 856,795 million shares. In its share capital, NewLink Genetics Corp (NASDAQ:NLNK) has 25.90 million outstanding shares.

Equities researchers at Noble Financial boosted their price objective on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) from $16.00 to $34.00 in a research report issued on Tuesday, American Banking reports. The firm currently has a “buy” rating on the stock. On Monday, shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) dropped -10.29% to close the day at $13.16. Company’s monthly performance is recorded as 77.84%. La Jolla Pharmaceutical Company (NASDAQ:LJPC) quarterly revenue growth is 102.46%.